A Phase I/II Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100) in Relapsed/Refractory Cancers of Children and Young Adults

Trial Profile

A Phase I/II Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100) in Relapsed/Refractory Cancers of Children and Young Adults

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Jul 2018

At a glance

  • Drugs BCT 100 (Primary)
  • Indications Acute myeloid leukaemia; Glioma; Neuroblastoma; Precursor cell lymphoblastic leukaemia-lymphoma; Sarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PARC
  • Most Recent Events

    • 22 May 2018 Planned initiation date changed from 1 Apr 2018 to 1 Jun 2018.
    • 17 Apr 2018 Status changed from not yet recruiting to recruiting.
    • 27 Mar 2018 As per ISRCTN recruitment is expected to start on 16 Apr 2018 and end on 16 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top